Navigation Links
SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease
Date:3/28/2009

G at one year in these same patient groups supports PCI as a rational alternative treatment option for these patients."

SYNTAX is the first randomized, controlled clinical trial to compare PCI using the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System to CABG in patients with left main disease and/or significant narrowing of all three coronary arteries (three-vessel disease). According to published guidelines, these patients are traditionally treated with CABG, and they have been excluded from most prior drug-eluting stent clinical trials. The goal of the SYNTAX trial is to explore whether it is safe and effective to treat some or all of these 'surgical' patients with PCI using the TAXUS Express2 stent.

The cost-effectiveness analysis compared the relative benefits in overall quality of life to the relative U.S. health care costs, for both PCI and CABG. In those patients with low or moderate lesion complexity, PCI was favored, providing more quality-adjusted life years and lower net medical costs than CABG. For patients with the most complex disease -- and in whom the increase in repeat revascularization for PCI versus CABG was greatest -- CABG provided slightly more quality-adjusted life years, with no significant difference in net medical costs at one year.

The results showed that both PCI and CABG demonstrated equivalent rates of "substantial improvement" in angina relief as compared to baseline at one, six and 12 months (57.6% PCI v. 58.3% CABG at 12 months) (p=statistically insignificant). The number of patients who reported being angina free was comparable for PCI and CABG at one month (64.4% v. 61.6%) and six months (68.5% v. 72.0%) (p=statistically insignificant for both), but was higher in the CABG group at 12 months (71.6% v. 76.3%) (p=0.05).

In addition, the study showed that total medical costs were $5,693 lower for PCI than for CABG for the initial hospitalization (
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease
2. SYNTAX Data Show Comparable Safety for Complex Patients Treated with TAXUS(R) Express2(TM) Stents and Bypass Surgery
3. New England Journal of Medicine Publishes Results from Boston Scientifics Landmark SYNTAX(TM) Trial
4. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
5. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
6. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
7. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
8. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
9. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
10. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
11. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... N.J. , March 26, 2015 IGI ... Jersey based specialty generic pharmaceutical company, today ... application (ANDA) to the U.S. Food and Drug Administration ... of ANDA submissions now pending at the FDA to ... CEO of the Company, commented, "On March 2, 2015, ...
(Date:3/26/2015)...  CNBC profiled MJ Freeway , a business software ... "How I Did It," which features companies with unique paths ... released yesterday, illustrates how two tech entrepreneurs from ... the marijuana industry. ... Poinsett and Jessica Billingsley used their experience in ...
(Date:3/26/2015)... 26, 2015 Editor Note: ... bottom . Investor-Edge has initiated coverage on ... Salix Pharmaceuticals Ltd (NASDAQ: SLXP ), Hospira Inc. ... ), and Akorn Inc. (NASDAQ: AKRX ). Free ... http://get.Investor-Edge.com/pdf/?c=Mylan&d=26-Mar-2015&s=MYL . The US markets declined on Wednesday, March ...
Breaking Medicine Technology:IGI Laboratories, Inc. Announces First ANDA Submission Of 2015 2MJ Freeway, Industry-Leading Software Solution for Cannabis Businesses, Featured in CNBC Special "How I Did It" 2Active Equities to Watch in the Pharma Industry -- Mylan, Salix Pharma, Hospira, VIVUS, and Akorn 2Active Equities to Watch in the Pharma Industry -- Mylan, Salix Pharma, Hospira, VIVUS, and Akorn 3Active Equities to Watch in the Pharma Industry -- Mylan, Salix Pharma, Hospira, VIVUS, and Akorn 4Active Equities to Watch in the Pharma Industry -- Mylan, Salix Pharma, Hospira, VIVUS, and Akorn 5
... LITTLE FALLS, N.J., Feb. 2, 2011 Projects ... provider of continuing medical education (CME/CE) activities, previously ... game-changing Living Medical eTextbook. Now the iPhone app ... recognized by iMedicalApps ( www.imedicalapps.com ) as one ...
... and PRINCETON, N.J., Feb. 2, 2011 Eli Lilly ... Squibb Company (NYSE: BMY ) announced today ... two global Phase III studies evaluating necitumumab, an investigational ... cell lung cancer (NSCLC). (Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO) ...
Cached Medicine Technology:Living Medical eTextbook iPhone App from Projects In Knowledge® Named to Top 20 List of Free Medical Apps 2Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 2Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 3Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 4Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 5Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 6Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 7Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 8Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 9Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 10
(Date:3/27/2015)... Airy Jeanine is a rising star. ... video for her debut song “Mama’s Girl”, launched on ... abstract styling effects, the thematic video for the rhythmic ... and assorted outlets. It will be integral in establishing, ... full-scale marketing strategy. The video promotion campaign spearheaded by ...
(Date:3/27/2015)... 27, 2015 “ VXi BlueParott Reveal ... monthly Tech Report, which features the latest and coolest ... expert and special reporter for NewsWatch, conducted the review ... noise-cancelling headset, eliminating 90% of ambient noise. , Today, ... and emails are important to any professional, voice calls ...
(Date:3/27/2015)... March 27, 2015 The ... Quaker-based, philanthropic, grant-making foundation committed to raising its ... healthcare is delivered. , The Scattergood Foundation and ... Behavioral Health Policy and Practice through the Annual ... Program App is designed to guide the ...
(Date:3/26/2015)... Dr. Rod J. Rohrich, who served as ... and has trained over 6500 surgeons through these meetings ... medicine (EBM), that is, the optimization of decision making ... often hear from rhinoplasty surgeons who describe ... not trying to stifle these discussions, we do want ...
(Date:3/26/2015)... The American College of Traditional Chinese Medicine ... of the DAOM Program as well as Marketing Basics for ... be hosted by Dr. Carla Wilson, who will give an ... how to prepare for the spring quarter. The webinar will ... April 1 and April 3. Attendees can log in from ...
Breaking Medicine News(10 mins):Health News:Airy Jeanine Releases ‘’Mama’s Girl” Official Music Video 2Health News:A Device to Tune out Background Noise was Recently Featured on NewsWatch Television 2Health News:SoundsLikeIBS Nominated For 3rd Annual Scattergood Innovation Award 2Health News:Dr. Rod Rohrich Explores Evidence Based Innovations and Safety at the 32nd Annual Dallas Rhinoplasty Symposium 2Health News:ACTCM Announces Upcoming Webinars 2
... seen with DHA, either in terms of prevention or ... Two trials that looked at whether the omega-3 fatty ... produced mixed results. , The studies were done because ... fish consumption to cognitive function," explained Bill Thies, chief ...
... A ... Meeting in Keystone, Colorado, (July 9-12) details the benefits and risks of repairing a torn ... ... More and more children are participating and getting hurt playing sports each year. A new ...
... , , NEW YORK ... Sub-Saharan Africa as president, Barack Obama today gave an historic speech ... address the deadly public health voids in many African countries, the ... mothers, noting "...too many still die from diseases that shouldn,t kill ...
... Mayo Clinic study may help physicians differentially ... study will be presented at the Alzheimer,s Association International ... , In this study, Mayo Clinic researchers developed ... neurodegenerative disorders: Alzheimer,s disease , frontotemporal lobar ...
... ... will join three other North American physicians as a 2009 American Orthopaedic Society ... ... John Bergfeld, MD, Cleveland Clinic Foundation, Director of Operating Room Management, will join three ...
... The Council for American Medical Innovation today applauded President ... head the National Institutes of Health (NIH). , ... ) , , "Dr. Collins is both a ... medical innovation," said Council President Dick Gephardt. "His passion ...
Cached Medicine News:Health News:Omega-3 Fatty Acid Falls Short in Alzheimer's Trials 2Health News:Omega-3 Fatty Acid Falls Short in Alzheimer's Trials 3Health News:Risks of Delaying ACL Reconstruction in Young Athletes May Be Too High, Study Shows 2Health News:Risks of Delaying ACL Reconstruction in Young Athletes May Be Too High, Study Shows 3Health News:Obama: 'Too Many Still Die from Diseases That Shouldn't Kill Them...' 2Health News:Mayo Clinic study using structural MRI may help accurately diagnose dementia patients 2Health News:Renowned, Cleveland Clinic Foundation, Orthopaedic Sports Medicine Surgeon, John Bergfeld, MD, Inducted into Sports Medicine Hall of Fame 2Health News:Council for American Medical Innovation Applauds Appointment of Geneticist Francis Collins to Head National Institutes of Health 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: